The LiBBY trial tested a THC-plus-CBD oil for agitation in hospice-eligible late-stage dementia and found clear relief. For spouses and partners, the findings point to faster calm at home and a concrete topic for the next hospice visit.
LiBBY stands for Life's End Benefits of cannabidiol and tetrahydrocannabinol. Agitation here means restlessness, shouting, pacing, or resisting care. The Alzheimer's Association describes the study as a 12-week, multicenter, randomized, double-blind, placebo-controlled Phase 2 trial in 120 patients, presented July 14, 2026 at AAIC London the Alzheimer's Association release.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How much did agitation improve?
- Why do home results matter for spouses?
- What did safety look like?
- What should you ask hospice next?
How much did agitation improve?
Starting dose was 2 mg THC plus 100 mg CBD twice daily. After a half-dose first week, it rose to 4 mg THC plus 200 mg CBD twice daily. Georgetown University School of Medicine gives these doses in its trial summary, with usual physician and hospice care continued. At week 2, the THC/CBD group improved faster.
News-Medical notes a 6.27-point greater drop in Cohen-Mansfield Agitation Inventory scores than placebo (-10.61 vs -4.35 points, p=0.0004) its AAIC report. By week 12, the gap reached 8.23 points favoring treatment. Clinician-rated improvement reached 87.2% on treatment versus 23.6% on placebo. Urban Health Today reports nearly 9 in 10 treated patients improved its home-based trial summary.
Why do home results matter for spouses?
Enrollees averaged about 80.5 years, with 55% women and 75% living in community homes. Study visits occurred at home, Urban Health Today notes, so the setting matches spousal care. About 58% came from historically underrepresented ethnoracial groups.
Agitation affects about half of people with dementia near end of life. Over one-third remain agitated despite benzodiazepines, opioids or antipsychotics, The Educated Patient reports. Less shouting, pacing, and resistance can mean fewer injuries, calmer nights, and less daily distress for the partner giving care.
What did safety look like?
Overall adverse events were similar between groups, 46.7% with THC/CBD versus 42.4% with placebo. Serious adverse events were more frequent with treatment, at 23.3%. MIMS Hong Kong, reporting LiBBY safety, notes investigators judged none drug-related and expected in frail end-of-life patients.
For a spouse, similar overall event rates do not mean no risk. Keep the hospice number close and report falls, excess sleepiness, breathing changes, or new confusion the same day. Frail patients can decline quickly for reasons unrelated to a new drug.
What should you ask hospice next?
LiBBY was small, hospice-eligible only, and used a purified investigational oil not sold in stores. Healio Neurology notes spouses should not substitute dispensary cannabis and should decide jointly with the hospice team.
Strength, purity, and dose differ outside trials. Bring the log to the next visit and ask what option fits your partner's hospice plan.
- Bring a 3-day log of shouting, pacing, sleep breaks, and care refusal
- Ask what agitation measures, sedatives, and safety checks hospice already uses
- Ask whether any cannabinoid trial or prescribed option fits your partner's plan
- Do not buy dispensary cannabis or change sedatives on your own
